FDA approves new drug for advanced kidney cancer

the U.SFood and Drug Administration approved a new drug Wednesday to extend the survival of patients with advanced kidney cancerThe drug, called Torisel, is manufactured by Wyeth Pharmaceuticals in the United States to treat renal cell carcinoma, a specific type of advanced kidney cancerThe FDA said in a statement that clinical trials have shown that taking Torisel can prolong the survival of patients with renal cell carcinomaIt is the thirddrug approved by the FDA to fight kidney cancerin nearly a year and a half2
January 2005
February 2005, a new drug, Dorgimi, was approved for sale, which slows the progression of kidney cancerJanuary 2
,,the new drug Sutent was approved for the marketwith accelerated approval,the drug could reduce theof kidney cancertumor,later clinical application found that it can also delay thelesions oftumorsThe data showabout 50,000 people in the U.Sare diagnosed with kidney cell cancer each year,about 85 percent of kidney cancer in U.Sadults is kidney cell carcinoma(
reprinted from "Xinhuanet")